Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 246

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 246
---
 2,477,566,800 Ordinary Shares upon the exercise of the pre-funded warrants, Series E Warrants and
Series F Warrants issued in the December 2023 underwritten public offering and private placement, including warrants exercised pursuant
to the terms of the Warrant Agreements (other than shares held in abeyance).

On July 22, 2024, we completed the Offerings with the Investors, pursuant to which we sold in the July 2024 Registered Direct Offering an aggregate of (i) 202,032 Depositary Shares and (ii) 11,157 July 2024 Pre-Funded Warrants, at a price per Depositary Share of $23.50, and a price per July 2024 Pre-Funded Warrant of $23.4975, and in the concurrent July 2024 Private Placement, we issued and sold to the Investors (x) Series J Warrants exercisable for 213,188 Depositary Shares, and (y) Series K Warrants to purchase an aggregate of 213,188 Depositary Shares. The warrants are immediately exercisable at an exercise price of $25.00 per Depositary Share, subject to adjustments for certain dilutive equity issuances. The aggregate gross proceeds to the Company were approximately $5.0 million. Additionally, we issued July 2024 Placement Agent Warrants to purchase 8,525 of our Depositary Shares in connection with the offering to Ladenburg and certain designees of Ladenburg.

On October 4, 2024, we effected
a ratio change to the Depositary Shares, pursuant to which the ratio of Ordinary Shares to Depositary Shares was changed such that one
Depositary Share represented 10,000 Ordinary Shares. Our Ordinary Shares were not affected by this change and no fractional Depositary
Shares were issued.

Options

We have established the Plan
to allow us to grant options to purchase Ordinary Shares (in the form of Depositary Shares) to employees and directors of the Company or any of its subsidiaries for the purpose of attracting, rewarding and retaining such persons. The Plan was originally adopted in December 2014 and amended on April 11, 2024 to govern the grant of tax-advantaged enterprise management incentive stock options and unapproved stock options by the Company. As of June 30, 2024, there were options to purchase 274,420,765 Ordinary Shares. The options lapse after ten years from the date of the grant. As of June 30,